Search results for: polyarticular JIA

FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP | October 21, 2020

The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis…

No Evidence to Support Biologic Switching Guidelines for JIA

Marilynn Larkin | April 1, 2020

NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…

What Do JIA Patients Experience? A New Case Study from the ARP Practice Committee

Talitha Cox, OT, MA, on behalf of the ARP Practice Committee | January 31, 2019

What does a new patient experience as symptoms develop and diagnosis is confirmed? The ARP Practice Committee is developing persona-based case studies to help answer this and other questions. The latest topic is juvenile idiopathic arthritis…

Treat JIA Without Slowing Growth

By Sue Pondrom | January 4, 2011

Etanercept does not impede normal height and weight development in these patients

2 Pediatric Indications Sought for Golimumab

Michele B. Kaufman, PharmD, BCGP | June 3, 2020

The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…

Opioid Investigated to Treat Acute & Chronic OA Pain; Plus New RA Treatment & More

Michele B. Kaufman, PharmD, BCGP | January 20, 2016

In Phase 2 trials, the oral opioid, CR845, has proved promising in treating pain in patients with hip and knee osteoarthritis. Olokizumab is being investigated to treat RA, and in Canada, adalimumab has been approved to treat polyarticular JIA in 2–4 year-olds…

Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis

Lara C. Pullen, PhD | January 2, 2013

In patients with simultaneous systemic and arthritic components of systemic juvenile idiopathic arthritis (SJIA), these components appear to be related mechanistically. Moreover, the inflammatory pathways of SJIA appear to be distinct from those seen in polyarticular JIA.

The 2022 ACR Awards of Distinction

Patrice Fusillo | December 8, 2022

During ACR Convergence 2022 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2022 Awards of Distinction, as well as the 2022 ACR Masters, recognized for their contributions to the field. See the November issue…

Baricitinib Promising for Juvenile Idiopathic Arthritis

Michele B. Kaufman, PharmD, BCGP | July 19, 2022

In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.

Never Too Late: Late-Breaking Abstracts Create Excitement

Jason Liebowitz, MD, FACR | July 15, 2022

EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…